You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Structural heart defects

Acoramidis for treating transthyretin amyloidosis with cardiomyopathy

  • Technology appraisal guidance
  • Reference number: TA1121
  • Published:  14 January 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final draft guidance
  2. Invitation to participate
  3. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6354
  4. Notes

History

Documents created during the development process.

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 129 KB)

    Published:
    12 December 2025
  • Committee papers (PDF 5.59 MB)

    Published:
    12 December 2025
  • Equality impact assessment (downloadable version) (PDF 129 KB)

    Published:
    12 December 2025

Invitation to participate

  • Final scope (PDF 152 KB)

    Published:
    07 July 2025
  • Final stakeholder list (PDF 136 KB)

    Published:
    07 July 2025
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 454 KB)

    Published:
    07 July 2025
  • Equality impact assessment (scoping) (PDF 103 KB)

    Published:
    07 July 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6354

  • Draft scope post referral (PDF 126 KB)

    Published:
    06 March 2025
  • Draft matrix post referral (PDF 50 KB)

    Published:
    02 April 2025

Notes

  • Note

Back to top